Advertisement

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation

  • Kristian Boasman
  • Matthew James Simmonds
  • Ciaren Graham
  • Yogen Saunthararajah
  • Ciro Roberto RinaldiEmail author
Letter to the Editor

Dear Editor,

Myelodysplastic syndromes (MDS) are malignant disorders of myeloid progenitors, characterised by bone marrow failure, peripheral cytopenias and progression to acute myeloid leukaemia (AML) [1]. Currently, the DNA methyltransferase 1 (DNMT1) depleting drugs 5-azacytidine and decitabine are the only drugs approved in the USA to treat all subtypes of MDS. Unfortunately, only 40–50% of patients achieve some response with these drugs, and these are not typically durable beyond some months or years. Whilst it is known, these drugs repressive epigenetic modifications of chromatin caused by DNA methylation, to presumably reactivate tumour suppressor genes [1], the specific gene/s targeted are unknown. PU.1 is a master transcription factor driving granulocyte and monocyte lineage fates, and partial loss-of-function of PU.1 has been shown to induce AML onset in mice and humans [2, 3]. The most frequent acquired mutation in de novo AMLs, is in nucleophosmin (NPM1). The NPM1 protein...

Notes

Acknowledgments

The authors thank Rachael Simpson for her contribution towards some of the experimental assays.

Funding

This study was funded by Celgene Pharma.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF (2017) New insight into the biology, risk stratification, and targeted treatment of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book 37:480–494CrossRefGoogle Scholar
  2. 2.
    Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P, Savvulidi F, Necas E, Hajkova H, Haskovec C, Cermak J, Krivjanska M, Trneny M, Laslo P, Jonasova A, Stopka T (2012) 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 26:1804–1811CrossRefGoogle Scholar
  3. 3.
    Laricchia-Robbio L, Premanand K, Rinaldi CR et al (2009) EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69:1633–1642CrossRefGoogle Scholar
  4. 4.
    Xiaorong G, Quteba E, Reda ZM et al (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest.  https://doi.org/10.1172/JCI97117
  5. 5.
    Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H, Takahashi S (2010) Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J Biol Chem 285:10300–10309CrossRefGoogle Scholar
  6. 6.
    Van der Weyden L, Rust AG, McIntyre RE et al (2013) Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene 32:397–402CrossRefGoogle Scholar
  7. 7.
    Rasmussen MH, Wang B, Wabl M, Nielsen AL, Pedersen FS (2009) Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nucleic Acids Res 37:4657–4671CrossRefGoogle Scholar
  8. 8.
    Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sønderby CK, Winther O, Rapin N, Porse BT (2016) BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res 44:D917–D924CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kristian Boasman
    • 1
  • Matthew James Simmonds
    • 1
  • Ciaren Graham
    • 2
  • Yogen Saunthararajah
    • 3
  • Ciro Roberto Rinaldi
    • 1
    Email author
  1. 1.School of Life Sciences, College of Science, Joseph Banks LaboratoriesUniversity of LincolnLincolnUK
  2. 2.School of Biological SciencesQueen’s University Belfast Medical Biology CentreBelfastUK
  3. 3.Department of Hematology and OncologyTaussig Cancer Institute, Cleveland ClinicClevelandUSA

Personalised recommendations